MeiraGTx (MGTX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking.

Do institutionals and insiders hold more shares of RXRX or MGTX?

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community prefer RXRX or MGTX?

MeiraGTx received 163 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 71.75% of users gave MeiraGTx an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 30 55.56%	Underperform Votes 24 44.44%
MeiraGTx	Outperform Votes 193 71.75%	Underperform Votes 76 28.25%

Which has more volatility & risk, RXRX or MGTX?

Recursion Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

Does the media favor RXRX or MGTX?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 8 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.16 beat Recursion Pharmaceuticals' score of 0.79 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RXRX or MGTX?

Recursion Pharmaceuticals presently has a consensus target price of $8.25, suggesting a potential upside of 71.52%. MeiraGTx has a consensus target price of $24.50, suggesting a potential upside of 299.67%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
MeiraGTx	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is RXRX or MGTX more profitable?

Recursion Pharmaceuticals has a net margin of -579.52% compared to MeiraGTx's net margin of -633.05%. Recursion Pharmaceuticals' return on equity of -76.56% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
MeiraGTx	-633.05%	-146.38%	-53.05%

Which has higher earnings & valuation, RXRX or MGTX?

MeiraGTx has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.49M	33.06	-$328.07M	-$1.66	-2.90
MeiraGTx	$33.28M	14.53	-$84.03M	-$2.13	-2.88

Summary

Recursion Pharmaceuticals beats MeiraGTx on 9 of the 17 factors compared between the two stocks.